• EVI

Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome Trust

Eveliqure's effort to develop a Shigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.


Eveliqure Biotechnologies announces today the grant of a Wellcome Trust Innovator Award that supports the early clinical development of its Shigella-ETEC combination vaccine with ~£500K and complements the previously secured ~€11 million funding from public sources for the vaccine’s development (Horizon2020, Austrian Wirtschaftsservice (AWS) and Austrian Research Promotion Agency, FFG). 


To read the full news release, please click this link:

https://dd0878df-7f1d-4cd4-99b5-1a0d62bc3ecf.filesusr.com/ugd/f57d6c_3353afd3041d463ab561df6f3a3af680.pdf